Robotic-assisted partial nephrectomy using the HugoTM robotic-assisted surgery platform: Initial experience and insights.

IF 1.9 4区 医学 Q3 UROLOGY & NEPHROLOGY
Adam Bobrowski, William Wu, Chelsea Angeles, Simon Czajkowski, Jason Y Lee
{"title":"Robotic-assisted partial nephrectomy using the Hugo<sup>TM</sup> robotic-assisted surgery platform: Initial experience and insights.","authors":"Adam Bobrowski, William Wu, Chelsea Angeles, Simon Czajkowski, Jason Y Lee","doi":"10.5489/cuaj.8951","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Robotic-assisted surgery (RAS) is a vital modality in the armamentarium of minimally invasive surgeons. The HugoTM RAS system (Medtronic<sup>®</sup>) is one of the newest platforms on the market and has little surgical outcomes data. We describe our early experience performing robotic-assisted partial nephrectomy (RAPNx) with the Hugo RAS platform.</p><p><strong>Methods: </strong>We conducted a retrospective review of patients who underwent a RAPNx with the Hugo RAS platform between April and December 2023 at the University Health Network in Toronto, ON. One surgeon performed all procedures using a three-arm transperitoneal approach. Anesthetic, operative, and pathologic reports were assessed to collect pre-, intra- and postoperative variables.</p><p><strong>Results: </strong>Eleven patients were included. The mean age was 51 years, 45.0% were female, and 63.6% had a right-sided mass. Mean tumor size was 2.9 cm. Mean warm ischemia time was 18.9 min (standard deviation [SD] 7.12) and mean estimated blood loss was 179 mL (SD 63.6). Mean robot docking time was 232 seconds (SD 106.5), mean total console time was 93 minutes (SD 21.4), and mean total operative time was 165.6 minutes (SD 34.1). There were no intraoperative complications. On pathology review, most tumors were a clear cell variant (72.7%) and staged pT1a (81.8%). All margins were negative. One patient sustained a port site infection.</p><p><strong>Conclusions: </strong>This is the first North American case series using the Hugo RAS platform for RAPNx. Our findings underscore that the platform is safe and effective for performing RAPNx with comparable outcomes to other robotic platforms.</p>","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cuaj-Canadian Urological Association Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5489/cuaj.8951","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Robotic-assisted surgery (RAS) is a vital modality in the armamentarium of minimally invasive surgeons. The HugoTM RAS system (Medtronic®) is one of the newest platforms on the market and has little surgical outcomes data. We describe our early experience performing robotic-assisted partial nephrectomy (RAPNx) with the Hugo RAS platform.

Methods: We conducted a retrospective review of patients who underwent a RAPNx with the Hugo RAS platform between April and December 2023 at the University Health Network in Toronto, ON. One surgeon performed all procedures using a three-arm transperitoneal approach. Anesthetic, operative, and pathologic reports were assessed to collect pre-, intra- and postoperative variables.

Results: Eleven patients were included. The mean age was 51 years, 45.0% were female, and 63.6% had a right-sided mass. Mean tumor size was 2.9 cm. Mean warm ischemia time was 18.9 min (standard deviation [SD] 7.12) and mean estimated blood loss was 179 mL (SD 63.6). Mean robot docking time was 232 seconds (SD 106.5), mean total console time was 93 minutes (SD 21.4), and mean total operative time was 165.6 minutes (SD 34.1). There were no intraoperative complications. On pathology review, most tumors were a clear cell variant (72.7%) and staged pT1a (81.8%). All margins were negative. One patient sustained a port site infection.

Conclusions: This is the first North American case series using the Hugo RAS platform for RAPNx. Our findings underscore that the platform is safe and effective for performing RAPNx with comparable outcomes to other robotic platforms.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Cuaj-Canadian Urological Association Journal
Cuaj-Canadian Urological Association Journal 医学-泌尿学与肾脏学
CiteScore
2.80
自引率
10.50%
发文量
167
审稿时长
>12 weeks
期刊介绍: CUAJ is a a peer-reviewed, open-access journal devoted to promoting the highest standard of urological patient care through the publication of timely, relevant, evidence-based research and advocacy information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信